Table 1.
Baseline characteristics of the study population.
| Variable | All patients (n = 196) | CT/TT carriers (n = 110) | CC carriers (n = 86) | P |
|---|---|---|---|---|
| Age (years) | 42 (38–45) | 43 (38–45) | 41 (39–45) | 0.9 |
| Male sex | 75% (147) | 79% (87) | 70% (60) | 0.14 |
| Plasma HCV-RNA (log IU/ml) | 6.63 (5.87–7.05) | 6.68 (6.02–7.06) | 6.49 (5.56–7.04) | 0.12 |
| Plasma HCV-RNA < 600 000 IU/ml | 25% (48) | 20% (22) | 30% (26) | 0.1 |
| HCV genotypes | 0.001 | |||
| 1 | 57% (112) | 68% (74) | 44% (38) | |
| 2 | 1% (2) | 0% (0) | 2% (2) | |
| 3 | 30% (58) | 19% (21) | 43% (37) | |
| 4 | 12% (23) | 13% (14) | 11% (9) | |
| Liver stiffness (kPa) | 6.8 (5.1–10) | 7 (5.1–10) | 6.2 (4.8–11) | 0.28 |
| Significant liver fibrosis (≥9.5 kPa) | 30% (59) | 31% (34) | 27% (23) | 0.53 |
| CD4 cell count (cells/µl) | 483 (378–692) | 502 (398–720) | 480 (359–646) | 0.23 |
| Plasma HIV RNA < 50 copies/ml | 74% (145) | 72% (78) | 78% (66) | 0.39 |
| Liver enzymes | ||||
| AST IU/ml | 56 (43–85) | 49 (41–73) | 64 (48–97) | 0.02 |
| ALT IU/ml | 75 (52–112) | 64 (48–99) | 85 (61–136) | 0.02 |
| GGT IU/ml | 66 (40–131) | 76 (43–153) | 60 (36–99) | 0.08 |
ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma-glutamyl transpeptidase. For continuous variables, all data are given as median (interquartile range).